Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-008 and Varenicline in Trigeminal Neuralgia (RELIEF)
NCT07596485Phase 2Recruiting
- Sponsor
- Kriya Therapeutics, Inc.
- Start
- Sep 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in trigeminal neuralgia (TN), sponsored by Kriya Therapeutics, Inc. Primary endpoint: Incidence and severity of adverse events at 12 months. Started Sep 2026; status: recruiting.
02
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT07596485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596485.